Four doses of carfilzomib increased PP2A activity, decreased AMPKα phosphorylation, and upregulated eNOS, Bip, Raptor, and LC3B expression. Graphs of PP2A (A). Activity (in pmol/mg protein; (n = 5 per group)) and (B). Expression (fold change of control). (C). Representative western blots and (D). Relative densitometry analysis of phosphorylated and total eNOS, AMPKα, and Akt levels normalized to α-actinin. (E). Representative western blots and (F) Relative densitometry analysis of phosphorylated and total mTOR, Raptor, and total Bip and LC3B normalized to α-actinin (n = 4–6 per group). All protein targets were run on the same gradient SDS page gel. Data are presented as mean ± SEM. two-tailed, unpaired t-test, * p < 0.05.